Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006

Journal of Clinical Pharmacology
Yaning WangJogarao V S Gobburu

Abstract

The End-of-Phase 2A meetings are proposed to identify opportunities to make innovative medical products available sooner and to increase the quality of drug applications through early meetings between sponsors and the FDA. This article summarizes the overall experience across 11 pilot End-of-Phase 2A meetings since 2004. Four case studies are presented in more detail to demonstrate the various issues and methods encountered at these meetings. Overall, industry and FDA scientists ranked these meetings to be "very helpful" (average score of 4 on a scale of 1 to 5). In almost all the instances the sponsors changed their drug development plans subsequent to these extensive quantitative analyses-based meetings. A draft Guidance is being developed to be issued in 2008, and we hope this initiative will be resourced by then.

References

Feb 1, 1989·Journal of Clinical Psychopharmacology·L MerlottiT Roth
Aug 1, 1993·Journal of Pharmacokinetics and Biopharmaceutics·N L DaynekaW J Jusko
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·H Kastrissios, T F Blaschke
Jun 8, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·G A FunkS Bonhoeffer
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Nov 12, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Raymond MillerRichard L Lalonde
Dec 16, 2005·The AAPS Journal·Venkatesh A BhattaramJogarao V S Gobburu
Jun 14, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Liping ZhangSandra R B Allerheiligen
Jan 30, 2007·Clinical Pharmacology and Therapeutics·L J Lesko
May 25, 2007·Clinical Pharmacology and Therapeutics·R L LalondeR Miller
Jun 1, 2007·Clinical Pharmacology and Therapeutics·J R Powell, J V S Gobburu

❮ Previous
Next ❯

Citations

Oct 28, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Carl C Peck
Sep 8, 2011·Journal of Pharmacokinetics and Pharmacodynamics·Hao Zhu, Yaning Wang
Jun 28, 2012·Journal of Pharmacokinetics and Pharmacodynamics·Jing Fang, Pravin R Jadhav
Oct 15, 2008·Annual Review of Pharmacology and Toxicology·Jogarao V S Gobburu, Lawrence J Lesko
Apr 1, 2010·Expert Opinion on Drug Discovery·Satyendra SuryawanshiBernd Meibohm
Nov 26, 2011·Thrombosis and Haemostasis·Todd S PerlsteinMark A Creager
Jun 18, 2009·Journal of Clinical Pharmacology·Stephanie LäerBernd Meibohm
Jul 18, 2009·Pharmaceutical Statistics·Pravin R JadhavJogarao V S Gobburu
Jun 6, 2008·Journal of Clinical Pharmacology·Henry J MalinowskiTing Ong
Oct 28, 2010·Journal of Clinical Pharmacology·Christoffer W TornøeJogarao V Gobburu
Jul 28, 2013·CPT: Pharmacometrics & Systems Pharmacology·K E KarlssonM O Karlsson
Oct 15, 2010·Journal of Clinical Pharmacology·Jogarao V S Gobburu
Oct 15, 2010·Journal of Clinical Pharmacology·Pravin R Jadhav, Steven E Kern
Mar 5, 2013·Biopharmaceutics & Drug Disposition·Dong-Yang LiuWilliam J Jusko
Jan 18, 2012·Journal of Clinical Pharmacology·Michael A TortoriciMarc Pfister
Mar 4, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Nick H G Holford, John G Nutt
Mar 3, 2009·Drug Metabolism and Pharmacokinetics·Bart A PloegerMeindert Danhof
Jan 15, 2014·Drug Metabolism and Pharmacokinetics·Kiyohiko NakaiYoshiaki Matsumoto
Jun 19, 2009·Clinical Pharmacology and Therapeutics·J V S Gobburu
May 25, 2016·Progress in Neurobiology·Margaret C Grabb, Jogarao V S Gobburu
Apr 16, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nitin MehrotraVikram Sinha
Jul 20, 2016·Expert Opinion on Drug Metabolism & Toxicology·Sven C van DijkmanOscar Della Pasqua
Mar 17, 2010·Expert Review of Clinical Pharmacology·Steven E Kern
Apr 11, 2018·British Journal of Clinical Pharmacology·Shaun S KumarCatherine M Sherwin
Sep 25, 2018·Journal of Clinical Pharmacology·Stephen J Balevic, Michael Cohen-Wolkowiez
Jul 9, 2010·Clinical Pharmacology and Therapeutics·N HolfordB A Ploeger
Jan 18, 2019·Clinical Pharmacology and Therapeutics·Yaning WangIssam Zineh
Feb 12, 2019·Clinical and Translational Science·Nina IsoherranenShiew-Mei Huang
Oct 11, 2017·Annual Review of Pharmacology and Toxicology·Kayla Ann AndrewsThaddeus Grasela
May 14, 2019·Clinical Pharmacology and Therapeutics·Rajanikanth MadabushiIssam Zineh
Jul 19, 2017·Proceedings of the National Academy of Sciences of the United States of America·Syndi BarishJana L Gevertz
Jul 22, 2010·Clinical Pharmacology and Therapeutics·M J GoldbergerA Yozviak
Jul 19, 2018·BMC Systems Biology·Guan-Sheng LiuTongli Zhang
Nov 25, 2011·Expert Review of Clinical Pharmacology·Kevin KrudysPeter I D Lee
Jun 1, 2017·Translational and Clinical Pharmacology·Sangmin Choe, Donghwan Lee
Aug 21, 2013·Cancer Research·Mary F McGuireEddy Pasquier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.